Video Experimental Relacionado
Updated: Sep 9, 2025
11:58
Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes
Published on: January 30, 2019
8.4K
Inhibidores de moléculas pequeñas dirigidos al ARN m6 A Modificadores para terapias contra el cáncer: últimos avances
Hairong Tang1,2,3, Ruijia Zhang1,2, Ao Zhang1,2,4,5,6
1Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
Journal of medicinal chemistry
|August 28, 2025
Resumen
Los inhibidores de moléculas pequeñas dirigidos a las proteínas modificadoras oncogénicas de la N6-metiladenosina (m6A) representan un tratamiento prometedor para el cáncer. Se discuten los avances recientes y las direcciones futuras en este campo de descubrimiento de fármacos epigenéticos de ARN.
Área de la Ciencia:
- La bioquímica
- Biología molecular
- En el campo de la oncología
Sus antecedentes:
- La N6-metiladenosina (m6A) es una modificación prevalente del ARN crucial para el metabolismo del ARN y la expresión de proteínas.
- Las modificaciones de m6A desreguladas y los modificadores de m6A aberrantes están relacionados con el inicio del cáncer, la progresión, la metástasis, el metabolismo y la evasión inmune.
Objetivo del estudio:
- Revisar los últimos avances en los inhibidores de moléculas pequeñas dirigidos a las proteínas modificadoras de m6A oncogénicas.
- Para discutir las limitaciones, los desafíos y las perspectivas futuras en el descubrimiento de fármacos epigenéticos de ARN m6A para la terapia del cáncer.
Principales métodos:
- Esta perspectiva sintetiza los resultados recientes de las investigaciones sobre inhibidores de moléculas pequeñas de proteínas modificadoras de m6A.
- Analiza el potencial terapéutico y los desafíos en el desarrollo de estos inhibidores para el tratamiento del cáncer.
Principales resultados:
- El desarrollo de inhibidores de moléculas pequeñas dirigidos a las proteínas modificadoras de m6A es una estrategia terapéutica contra el cáncer emergente y efectiva.
- El primer inhibidor de METTL3 de la clase STC-15 ha entrado en ensayos clínicos, lo que demuestra un progreso en este campo.
Conclusiones:
- La inhibición farmacológica de las proteínas modificadoras oncogénicas m6A desreguladas ofrece una nueva vía terapéutica para el cáncer.
- Se necesita más investigación y desarrollo para superar los desafíos y optimizar el descubrimiento de fármacos epigenéticos de ARN m6A para el tratamiento del cáncer.
Videos de Conceptos Relacionados
01:23RNA Interference
26.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.4K
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
01:23Types of RNA
64.8K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
64.8K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:53RNA Stability
33.9K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
33.9K